Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Disseminated disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    532 result(s) found for: Disseminated disease. Displaying page 1 of 27.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-002873-35 Sponsor Protocol Number: LEO 90010-I21 Start Date*: 2007-04-24
    Sponsor Name:LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S)
    Full Title: Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis
    Medical condition: Disseminated intravascular coagulation associated with severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013442 Disseminated intravascular coagulation LLT
    9.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002035-81 Sponsor Protocol Number: 2-001 Start Date*: 2007-10-22
    Sponsor Name:Artisan Pharma, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation
    Medical condition: Sepsis and disseminated intravascular coagulation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040047 Sepsis LLT
    9.1 10013442 Disseminated intravascular coagulation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004318-42 Sponsor Protocol Number: perfusie_pharma Start Date*: 2006-12-12
    Sponsor Name:Department of Neurology UMCG
    Full Title: Influence on brain perfusion and metabolism through pharmacologic agents
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011516-37 Sponsor Protocol Number: 14022009 Start Date*: 2009-05-29
    Sponsor Name:Danish Multiple Sclerosis Research Centre
    Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl...
    Medical condition: Multiple Sclerosis, with primary and secondary progressive courses.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014857-34 Sponsor Protocol Number: FAU-001 Start Date*: 2010-02-01
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T
    Medical condition: Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald’s criteria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028245 Multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000503-15 Sponsor Protocol Number: NEMESI-MS Start Date*: 2007-02-19
    Sponsor Name:AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI
    Full Title: Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of mem...
    Medical condition: patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001286-17 Sponsor Protocol Number: REMIT0401 Start Date*: 2006-09-08
    Sponsor Name:Fundación Española de Esclerosis Múltiple (FEDEM)
    Full Title: Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresi...
    Medical condition: Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003113-40 Sponsor Protocol Number: dexameth-001-2006 Start Date*: 2006-08-18
    Sponsor Name:Department of Neurology UMCG
    Full Title: Dexamethason for the treatment of exacerbations in multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023678-38 Sponsor Protocol Number: GR-2008-1138784 sottostudio Start Date*: 2011-04-20
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy.
    Medical condition: patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002626-11 Sponsor Protocol Number: ITT-PMS Start Date*: 2009-07-02
    Sponsor Name:Dept of Neurology
    Full Title: Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis
    Medical condition: Severe progressive multiple sclerosis in which there is no other documented treatment avalilable or allready tested. It is estimated that the prognosis for these patients are poor without any effec...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005148-28 Sponsor Protocol Number: 25643 Start Date*: 2005-05-26
    Sponsor Name:Merck Serono International S.A.
    Full Title: A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DK (Completed) EE (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) SK (Completed) LT (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-000759-40 Sponsor Protocol Number: TV - 5010/201 Start Date*: 2004-10-22
    Sponsor Name:TEVA
    Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
    Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005460-30 Sponsor Protocol Number: 2004.363/18 Start Date*: 2007-05-22
    Sponsor Name:OSPEDALI CIVILI DI LIONE
    Full Title: POPART’MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000393-47 Sponsor Protocol Number: SP000680 Start Date*: 2004-09-22
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-co...
    Medical condition: Treatment of spasticity in patients with Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005414-40 Sponsor Protocol Number: LEV-SM-2006 Start Date*: 2007-12-21
    Sponsor Name:AZIENDA SANITARIA N. 3 GENOVESE
    Full Title: Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study
    Medical condition: Patients with an established and stable Multiple Sclerosis (according to Poser criteria).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008554-23 Sponsor Protocol Number: AIR Start Date*: 2009-12-29
    Sponsor Name:The Multiple Sclerosis Research Group, Department of Clinical Neuroscience
    Full Title: Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation
    Medical condition: IFNβ-naïve patients fulfilling Poser or McDonald criteria for CDMS or MS and in whom a decision has been made to initiate treatment with RNF (Rebif New Formulation).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001496-11 Sponsor Protocol Number: 08020 Start Date*: 2010-01-15
    Sponsor Name:University of Nottingham
    Full Title: The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple Sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000296-12 Sponsor Protocol Number: T13/2014 Start Date*: 2014-04-15
    Sponsor Name:Turku University Hospital
    Full Title:
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000762-13 Sponsor Protocol Number: TV-5010/202 Start Date*: 2004-08-31
    Sponsor Name:TEVA ITALIA srl
    Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
    Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000606-23 Sponsor Protocol Number: 26756 Start Date*: 2006-11-23
    Sponsor Name:Merck, S.L.
    Full Title: Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase
    Medical condition: Not applicalbe
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 14:24:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA